Description
CDC-Enhanced Ibritumomab is a Fc-modified anti-CD20 therapeutic biobetter antibody. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Ibritumomab, Ibritumomab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
membrane spanning 4-domains A1
Background
This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants which encode the same protein.
Alternative Names
B1, S7, Bp35, CD20, CVID5, MS4A2, LEU-16
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Murine IgG1
Description
Ibritumomab tiuxetan, trade name Zevalin. The drug combines the monoclonal mouse IgG1 antibody ibritumomab with the chelator tiuxetan to treat relapsed or refractory B-cell non-Hodgkin's lymphoma. Ibritumomab tiuxetan is a monoclonal antibody radioimmunotherapy that targets the CD20 antigen on the surface of B cells and malignant B lymphocytes.
Indication
Follicular Non-Hodgkin's Lymphoma
Follicular Non-Hodgkin's Lymphoma Refractory
